Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSionna Therapeutics, Inc. Common Stock

Sionna Therapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.45 USD -0.25 ( 6.76%)
Last update at 2026-11-12T15:38:00Z
VOLUME
88402
Market Cap
310.63M

Momentum Score

…

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.39
Low
3.66
High
52 Week Price Range
4.01
Low
54.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutic candidates; publicly available detail on its specific programs is limited. Its long-term growth may benefit from clinical and regulatory progress, validation of its development platform and strategic partnerships, which could support value creation and make the company of interest to investors seeking early-stage biotech exposure.
Key risks include clinical or regulatory failure, high cash burn with the likely need for additional financing and dilution, scientific and competitive uncertainty, and execution risk across development programs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.70
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.03
ROE
-32.34%
Net Debt
-49.77M
ROCE
-23.95%
Diluted EPS TTM
-1.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -75.27M -61.69M -47.26M -40.24M
Net income -75.27M -61.69M -47.26M -40.24M
Selling general administrative 28.72M 13.27M 9.71M 6.77M
Gross profit -0.65M -0.67M - -
Reconciled depreciation 0.65M 0.67M 0.58M 0.12M
Ebit -75.27M -61.69M -47.26M -40.24M
Ebitda -74.62M -61.02M -46.68M -40.12M
Depreciation and amortization 0.65M 0.67M 0.58M 0.12M
Operating income -88.98M -70.56M -50.33M -41.37M
Other operating expenses 88.98M 70.56M 50.33M 41.37M
Interest income 13.29M 8.17M 2.77M 1.13M
Net interest income 13.29M 8.17M 2.77M 1.13M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 88.33M 69.89M 50.33M 41.37M
Cost of revenue 0.65M 0.67M - -
Total other income expense net 13.71M 8.87M 3.07M 1.13M
Net income from continuing ops -75.27M -61.69M -47.26M -40.24M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 325.95M 185.75M 51.95M 87.37M
Other current assets 5.54M 3.46M 0.69M 1.22M
Total liab 19.12M 349.46M 166.83M 157.29M
Total stockholder equity 306.83M -163.71M -114.88M -69.92M
Other current liab 9.67M 8.16M 6.59M 7.70M
Common stock 0.04M 0.01M 0.00M 0.00M
Capital stock 0.04M 0.01M 0.00M 0.00M
Retained earnings -256.35M -181.09M -119.40M -72.14M
Cash 58.45M 37.79M 38.52M 54.84M
Total current liabilities 11.71M 10.42M 8.04M 8.25M
Net debt -49.77M -28.04M -28.04M -54.84M
Short term debt 1.27M 1.07M 0.73M -
Short long term debt total 8.68M 9.75M 10.48M -
Other stockholder equity 562.60M -313.37M -144.53M -146.81M
Total current assets 241.42M 150.99M 39.21M 83.83M
Long term investments 74.42M 20.50M 0.00M -
Short term investments 177.43M 109.75M 0.00M 27.77M
Accounts payable 0.77M 1.19M 0.72M 0.56M
Accumulated other comprehensive income 0.54M 0.37M - -0.02M
Non currrent assets other 0.96M 3.96M 0.04M 0.96M
Non current assets total 84.53M 34.76M 12.74M 3.54M
Capital lease obligations 8.68M 9.75M 10.48M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -118.37M -126.91M 27.35M -29.26M
Total cashflows from investing activities -118.75M -126.91M 27.35M -29.26M
Total cash from financing activities 205.71M 178.97M 0.03M 110.86M
Net income -75.27M -61.69M -47.26M -40.24M
Change in cash 20.66M -0.73M -16.32M 45.52M
Begin period cash flow 38.75M 39.48M 55.80M 10.28M
End period cash flow 59.41M 38.75M 39.48M 55.80M
Total cash from operating activities -66.30M -52.79M -43.70M -36.07M
Issuance of capital stock 202.07M 181.33M 0.00M 110.79M
Depreciation -3.05M 0.67M 0.58M 0.12M
Other cashflows from financing activities 205.71M 178.97M 0.03M 110.86M
Capital expenditures 0.38M 0.03M 1.12M 1.87M
Change in working capital -2.65M -3.08M -0.78M 2.76M
Stock based compensation 12.07M 3.71M 2.26M 1.69M
Other non cash items 2.61M 7.60M 1.50M -0.40M
Free cash flow -66.67M -52.81M -44.81M -37.94M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
SION
Sionna Therapeutics, Inc. Common Stock		 -0.25
6.76%		 3.45 - - - 1.41
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Sionna Therapeutics, Inc. Common Stock

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

21 Hickory Drive, Waltham, MA, United States, 02451

617 819 2020

https://www.sionnatx.com

59

Name Title Year Born
Mr. Michael Cloonan M.B.A. President, CEO & Director 1972
Ms. Elena H. Ridloff C.F.A. Chief Financial Officer 1980
Ms. Caroline Stark Beer M.B.A. Chief Business Officer 1979
Dr. Greg Hurlbut Ph.D. Co-Founder & Senior VP of Discovery Research NA
Dr. Mark Munson Ph.D. Co-founder & Senior VP of Medicinal Chemistry NA
Mr. Andy Chu Vice President of Information & Technology NA
Ms. Jennifer Fitzpatrick J.D. Chief Legal Officer 1977
Ms. Sarah J. Spencer Vice President of Corporate Communications NA
Ms. Vanya Sagar Chief People Officer 1976
Dr. Charlotte McKee M.D. Chief Medical Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…